Provided by Tiger Trade Technology Pte. Ltd.

Mineralys Therapeutics, Inc.

23.63
-0.0900-0.38%
Post-market: 24.000.3700+1.57%19:41 EDT
Volume:928.30K
Turnover:22.06M
Market Cap:2.08B
PE:-5.40
High:24.34
Open:24.01
Low:23.55
Close:23.72
52wk High:47.65
52wk Low:22.30
Shares:88.16M
Float Shares:66.03M
Volume Ratio:0.56
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3763
EPS(LYR):-2.2900
ROE:-80.88%
ROA:-46.18%
PB:3.78
PE(LYR):-10.32

Loading ...

Buy Rating Reiterated on MLYS as Launch-HTN Data Highlight Lorundrostat’s Efficacy in Resistant CKD Hypertension; $54 Price Target Unchanged

TIPRANKS
·
Jun 02

Mineralys publishes ESH 2026 presentation on lorundrostat in CKD hypertension trial

Reuters
·
Jun 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Mineralys Therapeutics presents new data for lorundrostat

TIPRANKS
·
Jun 01

BRIEF-Mineralys Therapeutics Presents New Data From The Phase 3 Launch-Htn Trial Of Lorundrostat

Reuters
·
May 30

Mineralys Therapeutics Presents New Data From the Phase 3 Launch-Htn Trial of Lorundrostat in Participants With Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

THOMSON REUTERS
·
May 30

Mineralys Therapeutics: Lorundrostat Showed Significant Blood Pressure Reductions in Ckd Patients in Phase 3 Launch-Htn Trial

THOMSON REUTERS
·
May 30

Mineralys Therapeutics: Lorundrostat Significantly Reduced Urine Albumin-to-Creatinine Ratio in Trial

THOMSON REUTERS
·
May 30

Mineralys' pill cuts blood pressure in kidney disease patients

Reuters
·
May 30

Mineralys Therapeutics: Lorundrostat Demonstrated Favorable Safety Profile in Participants With and Without Chronic Kidney Disease Over 12 Weeks

THOMSON REUTERS
·
May 30

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

Dow Jones
·
May 29

Will Phase 3 Launch-HTN Success and Conference Spotlight Change Mineralys Therapeutics' (MLYS) Narrative?

Simply Wall St.
·
May 29

Mineralys Therapeutics to Present at Jefferies Global Healthcare Conference

Reuters
·
May 27

Mineralys Therapeutics shareholders approve Ernst & Young as auditor

Reuters
·
May 23

Mineralys CMO David Malcom Rodman disposes of 417 shares for $11,491.35

Reuters
·
May 20

Guggenheim Keeps Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
May 19

Mineralys presents Phase 3 Launch-HTN lorundrostat data in hypertension, CKD at ESH 2026

Reuters
·
May 19

BRIEF-Mineralys Therapeutics Announces Presentation Of New Data From The Late-Stage Launch-Htn Trial Of Lorundrostat

Reuters
·
May 19

Mineralys Therapeutics Announces Presentation of New Data From the Phase 3 Launch-Htn Trial of Lorundrostat at the 35TH European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

THOMSON REUTERS
·
May 19

Mineralys CMO David Malcom Rodman disposes of shares worth $648,330.57

Reuters
·
May 14